Management of Thrombocytopenia in Liver Cirrhosis

Understanding Thrombocytopenia in Cirrhosis

Approximately 80% of patients with cirrhosis have platelet counts below normal limits 3, 4
Severe thrombocytopenia (<50 × 10⁹/L) is uncommon in compensated disease but more frequent in decompensated cirrhosis 3, 4
Platelet counts <30 × 10⁹/L remain infrequent even in advanced disease 3, 4

Evidence does not support routine correction of platelet counts before procedures: low platelet count is not a reliable predictor of procedural bleeding risk 1, 2, 6
Prophylactic platelet transfusions have not been shown to reduce bleeding risk and may paradoxically increase it 1, 2
No high-quality data supports specific platelet thresholds before procedures 1, 2

FDA-approved thrombopoietin receptor agonists for thrombocytopenia in liver disease, such as avatrombopag and lusutrombopag, are indicated for treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure 1, 2, 7
Avatrombopag and lusutrombopag require completion of a 2-8 day course before the procedure and are superior to placebo in achieving platelet counts ≥50,000/μL 1, 7
Eltrombopag has an obsolete indication for thrombocytopenia related to interferon-based hepatitis C therapy and is not currently recommended for routine pre-procedural use due to excess thrombotic events 1, 7

For patients with platelet counts <30,000/μL, the overall clinical context should be considered rather than just the platelet number, as most bleeding is attributable to portal hypertension rather than the low platelet count itself 1, 7
For patients requiring anticoagulation, decisions should be individualized based on thrombosis extent, risk of extension, and bleeding risk factors, and anticoagulation should not be withheld in patients with moderate thrombocytopenia 8